The company said its revenue for Q2 2024 was $13,283 million, up 2% from $13,007 million a year earlier (3% on an operational basis). It raised its full-year revenue outlook to $59.5 to $62.5 billion, from the prior $58.5 to $61.5 billion.

1. 01

   The company said its revenue for Q2 2024 was $13,283 million, up 2% from $13,007 million a year earlier (3% on an operational basis). It raised its full-year revenue outlook to $59.5 to $62.5 billion, from the prior $58.5 to $61.5 billion.

2. 02

   Pfizer reported Q2 reported diluted EPS of $0.01 ($0.41 a year earlier) and adjusted diluted EPS of $0.60 ($0.67 a year earlier). The company said one-time costs of $1.3 billion tied to its Manufacturing Optimization Program negatively affected reported diluted EPS by $0.18.

3. 03

   The company said its Q2 revenue excluding Comirnaty and Paxlovid was $12.8 billion, up 14% operationally from a year earlier. Comirnaty revenue for the same quarter was $195 million, down 87% operationally, while Paxlovid revenue was $251 million, up 79% operationally.

4. 04

   The company said it launched phase 1 of its Manufacturing Optimization Program in May 2024 and expects savings of about $1.5 billion by the end of 2027. It said the one-time costs for this are about $1.7 billion, recorded mainly in 2024, with cash outlays expected mainly in 2025 and 2026.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.